Saturday, 15 September 2012

More news on Teriflunomide

Sanofi/Genzyme: modest efficacy sees Aubagio compete on price
Equities.com
Sanofi/Genzyme: modest efficacy sees Aubagio compete on price. The FDA has approved Aubagio, a once-daily, oral treatment for relapsing multiple sclerosis. Comtex News Network. Sep 14, 2012 (Datamonitor via COMTEX) -- Following the announcement ...
See all stories on this topic »


FDA Approves Genzyme's AUBAGIO ... - Yahoo! Finance
From Yahoo! Finance: Genzyme, a Sanofi company , announced today that the U.S. Food and Drug Administration has approved AUBAGIO® as a new ...
finance.yahoo.com/.../fda-approves-genzyme-aubagio-teriflun...

Recent posts of interest:

13 Sep 2012
MSers receiving teriflunomide 14 mg had a statistically significant reduction in annualised relapse rate and risk of sustained accumulation of disability. This double-blind, multi-center trial enrolled 1,169 MSers and compared .
13 Sep 2012
"For those of you who want more information I have uploaded Teriflunomide's highlights of prescribing information for you to review and download. I am expecting a lot of questions." CoI: multiple. Posted by Gavin Giovannoni ...
26 Jun 2012
Background:The Teriflunomide Multiple Sclerosis Oral (TEMSO) trial, a randomized, double-blind, placebo-controlled phase III study, demonstrated that teriflunomide significantly reduced annualized relapse rate (ARR), ...
07 Jun 2012
MSers receiving teriflunomide 14 mg had a statistically significant reduction in annualised relapse rate and risk of sustained accumulation of disability. This double-blind, multi-center ial enrolled 1,169 MSers and compared ...

No comments:

Post a Comment

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.